Gilbert Madrid
CEO
Laguna Tech USA
The startup develops a heart valve replacement device that integrates balloon-expandable and self-expanding technologies to treat aortic stenosis and regurgitation. This device enhances procedural simplicity and reliability, enabling medical professionals to achieve better patient outcomes through minimally invasive interventions.
- Biotechnology
- Healthcare Technology
- Medical Devices
Updated 21 months ago
Funding
Raised to date
$6.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Aortic stenosis and aortic regurgitation are significant valvular heart diseases, affecting a large percentage of the aging population. Current treatment options, including medication, open-heart surgery, and off-label TAVR devices, present limitations such as ineffectiveness for severe cases, high surgical risk for certain patients, and potential complications like embolization, paravalvular leaks, and heart failure.
Solution
Laguna Tech USA addresses these unmet needs with the ZETA Transcatheter Aortic Valve System, a state-of-the-art valve designed for both aortic stenosis and regurgitation. The ZETA valve combines the benefits of balloon-expandable systems for accurate positioning and reduced pacemaker rates with self-expanding features for secure anchoring. This hybrid approach simplifies the procedure, enhances reliability, and expands treatment options for patients who are not ideal candidates for traditional methods. The ZETA valve aims to provide physicians with an easy-to-use system requiring minimal training, ultimately improving patient outcomes.
Target Audience
The primary target audience includes interventional cardiologists and surgeons seeking minimally invasive solutions for treating aortic stenosis and regurgitation, as well as patients with valvular heart disease who are not suitable candidates for traditional open-heart surgery.
Features
- Hybrid design leveraging both balloon-expandable and self-expanding technologies
- Six flexible arms with markers for visibility under fluoroscopy, ensuring secure anchoring and accurate positioning
- Low valve height to improve coronary clearance
- Dry tissue technology eliminating glutaraldehyde to reduce throat and lung irritation
- Balloon-expanded anchoring mechanism for automatic pinning of native leaflets
- 16F delivery access system to accommodate more patients with smaller anatomies
- Delivery system with deflection, rotation, and telescoping control for easy adoption and precise placement
- Deflectable delivery catheter for high angulation aortic arches
- Atraumatic valve sheath cover to reduce trauma over the arch